vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and CATHAY GENERAL BANCORP (CATY). Click either name above to swap in a different company.
CATHAY GENERAL BANCORP is the larger business by last-quarter revenue ($222.8M vs $199.9M, roughly 1.1× Apellis Pharmaceuticals, Inc.). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs -29.5%, a 682.9% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs -5.9%). CATHAY GENERAL BANCORP produced more free cash flow last quarter ($363.7M vs $-14.3M). Over the past eight quarters, CATHAY GENERAL BANCORP's revenue compounded faster (12.8% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
APLS vs CATY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $222.8M |
| Net Profit | $-59.0M | $90.5M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | 50.9% |
| Net Margin | -29.5% | 653.4% |
| Revenue YoY | -5.9% | 19.5% |
| Net Profit YoY | -62.2% | 12.9% |
| EPS (diluted) | $-0.40 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $222.8M | ||
| Q3 25 | $458.6M | $210.6M | ||
| Q2 25 | $178.5M | $196.6M | ||
| Q1 25 | $166.8M | $187.8M | ||
| Q4 24 | $212.5M | $186.5M | ||
| Q3 24 | $196.8M | $189.5M | ||
| Q2 24 | $199.7M | $178.5M | ||
| Q1 24 | $172.3M | $175.2M |
| Q4 25 | $-59.0M | $90.5M | ||
| Q3 25 | $215.7M | $77.7M | ||
| Q2 25 | $-42.2M | $77.5M | ||
| Q1 25 | $-92.2M | $69.5M | ||
| Q4 24 | $-36.4M | $80.2M | ||
| Q3 24 | $-57.4M | $67.5M | ||
| Q2 24 | $-37.7M | $66.8M | ||
| Q1 24 | $-66.4M | $71.4M |
| Q4 25 | -25.6% | 50.9% | ||
| Q3 25 | 48.7% | 44.5% | ||
| Q2 25 | -18.6% | 49.0% | ||
| Q1 25 | -50.0% | 46.1% | ||
| Q4 24 | -12.3% | 46.5% | ||
| Q3 24 | -24.0% | 41.2% | ||
| Q2 24 | -14.7% | 40.7% | ||
| Q1 24 | -36.0% | 45.7% |
| Q4 25 | -29.5% | 653.4% | ||
| Q3 25 | 47.0% | 36.9% | ||
| Q2 25 | -23.6% | 39.4% | ||
| Q1 25 | -55.3% | 37.0% | ||
| Q4 24 | -17.1% | 587.9% | ||
| Q3 24 | -29.2% | 35.6% | ||
| Q2 24 | -18.9% | 37.4% | ||
| Q1 24 | -38.5% | 40.8% |
| Q4 25 | $-0.40 | $1.33 | ||
| Q3 25 | $1.67 | $1.13 | ||
| Q2 25 | $-0.33 | $1.10 | ||
| Q1 25 | $-0.74 | $0.98 | ||
| Q4 24 | $-0.30 | $1.11 | ||
| Q3 24 | $-0.46 | $0.94 | ||
| Q2 24 | $-0.30 | $0.92 | ||
| Q1 24 | $-0.54 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | — |
| Total DebtLower is stronger | — | $119.1M |
| Stockholders' EquityBook value | $370.1M | $2.9B |
| Total Assets | $1.1B | $24.2B |
| Debt / EquityLower = less leverage | — | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
| Q4 25 | — | $119.1M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $119.1M | ||
| Q1 25 | — | $119.1M | ||
| Q4 24 | — | $119.1M | ||
| Q3 24 | — | $119.1M | ||
| Q2 24 | — | $119.1M | ||
| Q1 24 | $93.1M | $119.1M |
| Q4 25 | $370.1M | $2.9B | ||
| Q3 25 | $401.2M | $2.9B | ||
| Q2 25 | $156.3M | $2.9B | ||
| Q1 25 | $164.2M | $2.9B | ||
| Q4 24 | $228.5M | $2.8B | ||
| Q3 24 | $237.1M | $2.8B | ||
| Q2 24 | $264.3M | $2.8B | ||
| Q1 24 | $266.7M | $2.8B |
| Q4 25 | $1.1B | $24.2B | ||
| Q3 25 | $1.1B | $24.1B | ||
| Q2 25 | $821.4M | $23.7B | ||
| Q1 25 | $807.3M | $23.2B | ||
| Q4 24 | $885.1M | $23.1B | ||
| Q3 24 | $901.9M | $23.3B | ||
| Q2 24 | $904.5M | $23.2B | ||
| Q1 24 | $831.9M | $23.4B |
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | 0.35× | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $368.6M |
| Free Cash FlowOCF − Capex | $-14.3M | $363.7M |
| FCF MarginFCF / Revenue | -7.1% | 163.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.2% |
| Cash ConversionOCF / Net Profit | — | 4.07× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | $672.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | $368.6M | ||
| Q3 25 | $108.5M | $150.6M | ||
| Q2 25 | $4.4M | $64.0M | ||
| Q1 25 | $-53.4M | $99.0M | ||
| Q4 24 | $19.4M | $329.2M | ||
| Q3 24 | $34.1M | $81.2M | ||
| Q2 24 | $-8.3M | $72.9M | ||
| Q1 24 | $-133.0M | $88.2M |
| Q4 25 | $-14.3M | $363.7M | ||
| Q3 25 | $108.3M | $150.1M | ||
| Q2 25 | $4.4M | $62.7M | ||
| Q1 25 | $-53.4M | $96.3M | ||
| Q4 24 | $19.3M | $325.5M | ||
| Q3 24 | — | $80.0M | ||
| Q2 24 | $-8.4M | $72.4M | ||
| Q1 24 | $-133.3M | $87.3M |
| Q4 25 | -7.1% | 163.2% | ||
| Q3 25 | 23.6% | 71.3% | ||
| Q2 25 | 2.5% | 31.9% | ||
| Q1 25 | -32.0% | 51.2% | ||
| Q4 24 | 9.1% | 174.6% | ||
| Q3 24 | — | 42.2% | ||
| Q2 24 | -4.2% | 40.5% | ||
| Q1 24 | -77.3% | 49.8% |
| Q4 25 | 0.1% | 2.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.5% |
| Q4 25 | — | 4.07× | ||
| Q3 25 | 0.50× | 1.94× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 1.42× | ||
| Q4 24 | — | 4.10× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.09× | ||
| Q1 24 | — | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CATY
Segment breakdown not available.
